Crossmark

Ranibizumab port delivery system: a clinical perspective

Crossref DOI link: https://doi.org/10.1136/bmjophth-2022-001104

Published Online: 2022-09-26

Published Print: 2022-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Eichenbaum, David A https://orcid.org/0000-0003-0654-0668
Ahmed, Abrahim

Hiya, Farhan
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03683251 at ClinicalTrials.gov

Documents that mention this clinical trial

Ranibizumab port delivery system: a clinical perspective
https://doi.org/10.1136/bmjophth-2022-001104

nct03683251 at ClinicalTrials.gov

Documents that mention this clinical trial

Ranibizumab port delivery system: a clinical perspective
https://doi.org/10.1136/bmjophth-2022-001104

nct03953079 at ClinicalTrials.gov

Documents that mention this clinical trial

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
https://doi.org/10.1136/bmjophth-2019-000398

Ranibizumab port delivery system: a clinical perspective
https://doi.org/10.1136/bmjophth-2022-001104

nct04747197 at ClinicalTrials.gov

Documents that mention this clinical trial

Ranibizumab port delivery system: a clinical perspective
https://doi.org/10.1136/bmjophth-2022-001104
License Information

License valid from 2022-09-26